Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CORON-ACT - a Multicenter, Double-blind, Randomized Controlled Phase II Trial on the Efficacy and Safety of Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)

NCT04335071 is registered in ClinicalTrials.gov with Insel Gruppe AG, University Hospital Bern as lead sponsor.

NCT NCT04335071
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04335071 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CORON-ACT - a Multicenter, Double-blind, Randomized Controlled Phase II Trial on the Efficacy and Safety of Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)
Lead sponsor
Insel Gruppe AG, University Hospital Bern
Phase
Phase 2
Overall status
Terminated
Start date
April 26, 2020
Completion date
September 27, 2020
Enrollment
5 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2 infection